Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End point reduction in hypertension (LIFE) study Academic Article uri icon

Overview

MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Atrial Fibrillation
  • Cardiovascular Diseases
  • Cause of Death
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan

abstract

  • Losartan is more effective than atenolol-based therapy in reducing the risk of the primary composite end point of cardiovascular morbidity and mortality as well as stroke and cardiovascular death in hypertensive patients with ECG LV hypertrophy and AF.

publication date

  • March 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2004.06.080

PubMed ID

  • 15734614

Additional Document Info

start page

  • 705

end page

  • 11

volume

  • 45

number

  • 5